导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 33.47% | 95/4773 |
| 近一周 | 1.53% | 296/5465 |
| 近一月 | -3.40% | 2468/5421 |
| 近一季 | -10.21% | 3719/5231 |
| 近半年 | 30.39% | 75/4920 |
| 近一年 | 37.60% | 148/4394 |
| 近两年 | 192.64% | 100/2954 |
| 近三年 | 161.97% | 33/2253 |
| 成立以来 | 54.36% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.72% 4180/4961 |
95.34% 123/5312 |
- - |
- - |
| 2025 | 56.43% 308/4813 |
3.22% 1148/3635 |
1.23% 2413/4076 |
56.89% 166/4524 |
-4.57% 3466/4813 |
| 2024 | 24.20% 299/3463 |
-6.17% 2018/2808 |
5.18% 195/3014 |
13.26% 2205/3129 |
11.11% 240/3463 |
| 2023 | 3.41% 282/2656 |
16.28% 202/2280 |
-4.44% 1171/2385 |
-8.01% 1653/2515 |
1.17% 103/2655 |
| 2022 | -35.99% 1735/2207 |
-24.09% 1754/1919 |
0.95% 1513/2016 |
-18.15% 1686/2113 |
2.06% 1053/2208 |
| 2021 | 16.91% 254/1822 |
-6.75% 1035/1255 |
21.86% 130/1330 |
-6.32% 914/1466 |
9.82% 110/1822 |
| 2020 | - - |
- - |
- - |
- - |
- - |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 申万中证申万电子行业投资指数(LOF)C VS. 长安沪深300非周期A(740101) |